1 Day
Source:
Financial Times
AstraZeneca investors express merger worries
Shareholders are raising concerns about a potential $400 billion merger between an undisclosed company and Bristol Myers Squibb, citing risks related to upcoming patent expirations and antitrust issues.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)